Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)
View Patent ↗Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein.
1. A method of treating a subject suffering from an inflammatory condition comprising:
administering to the subject in need thereof an effective amount of an inhibitor of Cold-Inducible RNA-binding Protein (a CIRP inhibitor);
wherein the inflammatory condition is ischemia, organ ischemia-reperfusion injury, sepsis, or sepsis-septic shock; and
wherein the CIRP inhibitor is an antibody or a functional fragment thereof that specifically binds to CIRP; and
wherein the antibody or functional fragment thereof inhibits one or more biological activities of CIRP.
2. The method of claim 1 , wherein the antibody is a polyclonal antibody.
3. The method of claim 1 , wherein the antibody is a monoclonal antibody.
4. The method of claim 1 , wherein the antibody is a chimeric antibody, human antibody, or humanized antibody.
5. The method of claim 1 , wherein the antibody is a single chain antibody.
6. The method of claim 1 , wherein the subject is a human.
7. The method of claim 1 , wherein the CIRP inhibitor is a monoclonal antibody or a functional fragment thereof that specifically competes for binding to CIRP against rabbit polyclonal antiserum against CIRP raised by injecting rabbits with purified recombinant CIRP of SEQ ID NO: 1.